1. Home
  2. EYPT vs PHLT Comparison

EYPT vs PHLT Comparison

Compare EYPT & PHLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • EYPT
  • PHLT
  • Stock Information
  • Founded
  • EYPT N/A
  • PHLT 1976
  • Country
  • EYPT
  • PHLT United States
  • Employees
  • EYPT N/A
  • PHLT N/A
  • Industry
  • EYPT Biotechnology: Laboratory Analytical Instruments
  • PHLT Other Consumer Services
  • Sector
  • EYPT Industrials
  • PHLT Consumer Discretionary
  • Exchange
  • EYPT Nasdaq
  • PHLT Nasdaq
  • Market Cap
  • EYPT 741.0M
  • PHLT 601.2M
  • IPO Year
  • EYPT N/A
  • PHLT N/A
  • Fundamental
  • Price
  • EYPT $14.01
  • PHLT $7.63
  • Analyst Decision
  • EYPT
  • PHLT Buy
  • Analyst Count
  • EYPT 0
  • PHLT 2
  • Target Price
  • EYPT N/A
  • PHLT $7.88
  • AVG Volume (30 Days)
  • EYPT 659.8K
  • PHLT 1.6M
  • Earning Date
  • EYPT 08-06-2025
  • PHLT 11-05-2025
  • Dividend Yield
  • EYPT N/A
  • PHLT N/A
  • EPS Growth
  • EYPT N/A
  • PHLT N/A
  • EPS
  • EYPT N/A
  • PHLT N/A
  • Revenue
  • EYPT $51,898,000.00
  • PHLT $137,357,000.00
  • Revenue This Year
  • EYPT N/A
  • PHLT $12.38
  • Revenue Next Year
  • EYPT N/A
  • PHLT $10.09
  • P/E Ratio
  • EYPT N/A
  • PHLT N/A
  • Revenue Growth
  • EYPT 2.99
  • PHLT 15.21
  • 52 Week Low
  • EYPT $3.91
  • PHLT $2.17
  • 52 Week High
  • EYPT $14.37
  • PHLT $7.74
  • Technical
  • Relative Strength Index (RSI)
  • EYPT 77.25
  • PHLT 81.43
  • Support Level
  • EYPT $11.38
  • PHLT $7.56
  • Resistance Level
  • EYPT $12.24
  • PHLT $7.67
  • Average True Range (ATR)
  • EYPT 0.74
  • PHLT 0.03
  • MACD
  • EYPT 0.13
  • PHLT -0.14
  • Stochastic Oscillator
  • EYPT 89.80
  • PHLT 63.64

About EYPT EyePoint Pharmaceuticals Inc.

EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert E and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.

About PHLT Performant Healthcare Inc. Common Stock

Performant Healthcare Inc provides solutions to payers in the healthcare industry to identify, prevent, and recover waste and improper payments by leveraging technology, analytics, and proprietary data assets.

Share on Social Networks: